A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically confirmed hepatocellular carcinoma (without fibro-lamellar subtype) * Prior treatment with at least 1 systemic agent, with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that (those) agent(s) * Not a candidate for curative treatments (e.g. resection, transplantation) * Child-Pugh A (score of 5-6) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate hematologic, hepatic and renal function * Ability to provide, for central review, a tumor tissue sample to determine the level of GPC-3 expression by IHC * Measurable disease by RECIST criteria Exclusion Criteria: * Child Pugh B or C * Known hepatocellular carcinoma with fibro-lamellar histology * Known brain or leptomeningeal metastases * Active infectious diseases requiring treatment except for hepatitis B and C * History of organ allograft including liver transplant * Anticipated or ongoing administration of anticancer therapies other than those administered in this study * Anticancer treatment within 2 weeks prior to entering the study * Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies * Patients receiving interferon therapy * Pregnant or lactating women * Known HIV positivity or AIDS-related illness * History of significant hypersensitivity to similar agents (monoclonal antibody, protein-included drugs, Chinese hamster ovary products)